Efficacy and safety of 40 mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single …
A Otsuki, N Inoshima, K Tochigi, H Ito… - Thoracic …, 2024 - Wiley Online Library
Osimertinib is a first‐line or adjuvant therapy for non‐small cell lung cancer (NSCLC)
harboring an epidermal growth factor receptor (EGFR) mutation. However, owing to the …
harboring an epidermal growth factor receptor (EGFR) mutation. However, owing to the …